Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated February 20, 2025, reports on the vesting of Conditional Share Awards under the Share Value Plan and subsequent share sales to meet tax liabilities. The transactions occurred on February 17, 2025, involving Persons Discharging Managerial Responsibilities (PDMRs).
Key Financial Metrics
The filing does not contain company-wide financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific equity transactions for two executives:
- Transaction Price: £14.1829 per Ordinary Share.
- Instrument: Ordinary shares of 31 1/4 pence each (ISIN: GB00BN7SWP63).
- Transaction Date: February 17, 2025.
Material Changes and Transaction Details
The filing discloses the following specific transactions related to awards granted in 2022:
- Tony Wood (Chief Scientific Officer):
- Vested 24,638 Ordinary Shares.
- Sold 11,580 Ordinary Shares on the London Stock Exchange (XLON) to meet tax liabilities.
- Victoria Whyte (Company Secretary):
- Vested 10,050 Ordinary Shares.
- Sold 4,724 Ordinary Shares on the London Stock Exchange (XLON) to meet tax liabilities.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on business performance, risks, contingencies, or unusual items. The document is strictly a regulatory notification of insider share movements.
Investor Verification Checklist
- Verify the total number of shares retained by Tony Wood and Victoria Whyte post-tax sale.
- Confirm the tax rate implied by the ratio of shares sold to shares vested for each executive.
- Check the London Stock Exchange (XLON) trading data for February 17, 2025, to validate the execution price of £14.1829.
- Review the original 2022 Share Value Plan grant terms to understand the vesting conditions met.